VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment Fully biological...